

FANCD2 knockdown with shRNA interference enhances the ionizing radiation sensitivity of nasopharyngeal carcinoma CNE-2 cells

Yilin BAO, Huajun FENG, Feipeng ZHAO, Lijun ZHANG, Shengen XU, Conghong ZHANG, Chong ZHAO, Gang QIN*

Department of Otolaryngology-Head and Neck Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou, China

*Correspondence: qin-lzm@163.com

Received May 11, 2020 / Accepted August 3, 2020

Fanconi anemia complementation group D2 (FANCD2) has been associated with the sensitivity of tumor cells to DNA crosslinking damaging agents in certain solid tumors. However, its role in nasopharyngeal carcinoma (NPC) is still unclear. In the present study, the role of *FANCD2* in the response of NPC CNE-2 cells to radiation was investigated. A CNE-2 cell model with stable *FANCD2* silencing was constructed by lentiviral transfection. Fluorescence quantitative PCR and western blotting were used to evaluate *FANCD2* expression in CNE-2 cells. The biological impact of *FANCD2* silencing on the response of CNE-2 cells to radiation was investigated *in vitro* and *in vivo*. The microarray technology, western blotting, and immunohistochemistry were used to analyze the proteins involved in related pathways after irradiation to investigate the underlying mechanism. Lentivirus-mediated shRNA interference stably silenced the *FANCD2* gene in CNE-2 cells. *In vitro*, in the *FANCD2*-silenced group, cell proliferation was significantly inhibited, apoptosis was increased, and the cell cycle was arrested at the G2/M phase after irradiation. *In vivo*, *FANCD2* silencing slowed tumor growth, as the volume and weight of the xenograft tumors were significantly decreased. Both *in vitro* and *in vivo*, the differentially expressed genes NUPR1, FLI1, and FGF21 were downregulated in the *FANCD2*-silenced group. Our results show that *FANCD2* silencing affected the sensitivity of CNE-2 cells to ionizing radiation by regulating cell proliferation, apoptosis, and cell cycle distribution. The mechanism might be associated with changes in NUPR1, FLI1, and FGF21 protein expression due to the *FANCD2* silencing. This study provides a promising target for NPC radiotherapy.

Key words: Fanconi anemia complementation group D2, Fanconi anemia, nasopharyngeal carcinoma, radiotherapy

Nasopharyngeal carcinoma (NPC) is a malignant tumor that frequently occurs in the nasopharyngeal mucosal epithelium; its incidence is not high worldwide, with an overall incidence lower than 1/10,000 [1, 2]. In 2012, in total, there were 86,700 new NPC patients and 50,800 deaths worldwide, of which 71% occurred in Asia [3]. China is among the regions with the highest incidence of NPC, which exhibits regional distribution characteristics; Guangdong, Guangxi, and Fujian are areas with high incidences of NPC. In 2015, there were 60,600 new cases of NPC in China and 34,100 new deaths, and the number of new cases among males was approximately 2.5 times that among females [4]. There is no unified standard for the pathological categorization of NPC [5]. According to the World Health Organization (WHO) standards, NPC can be divided into keratinizing and nonkeratinizing squamous cell carcinoma or differentiated nonkeratinizing carcinoma and nondifferentiated carcinoma. Radiation therapy is the preferred treatment method. However, currently, effective treatment for cases insensitive

to radiation therapy or those who relapse after irradiation is lacking. Therefore, exploring a new treatment method that can increase sensitivity to NPC radiotherapy has become a research objective.

Fanconi anemia (FA) is a rare autosomal recessive genetic disease and its main characteristics are progressive bone marrow failure (BMF), endocrine dysfunction, tumor susceptibility, and premature dysfunction of multiple organs. Currently, it is believed that the pathogenesis of FA is associated with DNA damage repair disorders, inflammatory stress, mitochondrial dysfunction, and epigenetic changes [6]. Studies have shown that FA patients are sensitive to ionizing radiation and DNA crosslinkers such as mitomycin C and cisplatin [7], whose mechanism is to mainly inhibit the repair of DNA strand-crosslinking damage caused by the inactivation of the FA pathway [8]. To date, 22 genes involved in the FA pathway have been discovered, and most encode proteins involved in DNA damage repair, especially the repair of DNA crosslink damage,

apoptosis, cell cycle regulation, gene transcription, and the maintenance of genome stability. Mutations and deletions in these different genes are also considered the molecular basis of FA development [9–11]. It has been reported that in patients with head and neck squamous cell carcinoma (HNSCC), the mutation rate in the FA pathway is close to 40% [12]. The risk of HNSCC and gynecological squamous cell carcinoma in adolescents and adults with FA is increased 500-fold. However, the specific mechanism remains to be elucidated [13]. The monoubiquitination or deubiquitination of *FANCD2*, which is a key protein in the FA pathway, can lead to FA pathway inactivation, which in turn increases the sensitivity of cells to DNA crosslinking damage [14–16]. Experimental studies involving mice have found that *FANCD2* regulates the transcription of stress genes in a DNA-independent manner while enhancing the ability of cells to resist DNA damage [17]. *FANCD2*-deficient mice exhibit persistent endogenous DNA damage in hematopoietic stem cells and progressive BMF [18]. The upregulation of *FANCD2* expression could increase the survival rate of *BRCA1* and *BRCA2* gene-deficient tumor cells by recruiting alternative DNA damage proteins, changing the cell cycle, and maintaining replication fork stability [19, 20]. Studies have shown that *FANCD2* expression is high in metastatic melanoma [21], colorectal cancer [22], and human glioblastoma [23], and further studies have shown that tumor cells with high *FANCD2* expression exhibit proliferation and survival characteristics. However, to date, no studies have investigated *FANCD2* and NPC radiotherapy. The aim of this study was to investigate the effect of *FANCD2* silencing by short-hairpin RNA (shRNA) interference on the sensitivity of the NPC cell line CNE-2 to radiotherapy and explore the related mechanism to provide new targets and ideas for NPC radiotherapy.

Materials and methods

Cell lines and cell culture. The NPC cell line CNE-2 was a generous gift from the Department of Otolaryngology-Head and Neck Surgery, Nanfang Hospital, Southern Medical University, China. This study included an experimental group (CNE-2sh: CNE-2 cells with *FANCD2* expression silencing using an effective shRNA-*FANCD2* interference sequence), a negative control group (CNE-2NC: CNE-2 cells transfected with an ineffective interfering sequence), and a blank control group (CNE-2: wild-type CNE-2 cells without any treatment). The CNE-2 cells were cultured in Roswell Park Memorial Institute 1640 medium (RPMI-1640; Gibco, USA) supplemented with 10% fetal bovine serum (FBS; Biological Industries, Israel), 100 U/ml penicillin, and 100 µg/ml streptomycin. The cells were maintained in a saturated humidified incubator at a constant-temperature of 37°C at 5% CO₂. Puromycin (InvivoGen, San Diego, CA, USA) was added to the experimental group and negative control group as a screening reagent at a final concentration of 2 µg/ml.

Construction of the *FANCD2* shRNA lentiviral vector and cell transfection. The design of the *FANCD2* shRNA interference sequence, the construction of the PLKO.1 vector, and the packaging of the lentivirus particles were completed by Shanghai Zhong Qiao Xin Zhou Biotechnology Co., Ltd., China. The *FANCD2* shRNA interference sequence was CCGGCGTCTATTAGATTGGAGGATTCTCGAGATCCTCCAATCTAATAGACGTTTTTG. The NPC cell line CNE-2 was infected with recombinant lentiviruses and *FANCD2* stably silenced cell lines were obtained by continuous selection using puromycin (2 µg/ml).

The relative expression level of *FANCD2* was verified by fluorescence quantitative PCR. Total RNA was extracted from three groups of cells according to the instructions of the RNA extraction kit (Tiangen Biotech Co., China). Then, reverse transcription was performed to synthesize cDNA according to the kit instructions (Takara Bio Co., China). *FANCD2* gene amplification, to obtain the desired products and data, was performed according to the instructions of the fluorescence quantitative PCR reagent kit (Takara Bio Co., China) as follows: pre-denaturation at 95°C for 30 seconds, followed by 40 cycles of 95°C for 5 seconds and 60°C for 30 seconds. The relative expression levels of *FANCD2* mRNA in the three groups of cells were calculated. The primer sequences were as follows: *FANCD2* qF: GGAGTCCATGTCTGCTAAAGAG and *FANCD2* qR: CAATGTGCTT-TAACCGAGTGAG.

Radiation exposure. Cell and animal irradiation were performed using a Siemens linear accelerator (SIEMENS AG, Germany). Irradiation was conducted at room temperature, and the radiation dose rate was 200 cGy/min.

Colony formation assay. A preset concentration of cells in the logarithmic growth phase were seeded in 6-cm dishes, and after 24 h of incubation, the cells were irradiated (0, 2, 4, 6, 8, and 10 Gy). The cells were continuously cultured for 14 days after irradiation, and the colonies were fixed in 4% paraformaldehyde, stained with crystal violet, rinsed, and dried. The number of colonies containing >50 cells was counted under an inverted microscope. The colony formation rate was calculated (clone formation rate = number of clones/number of cells seeded × 100%). GraphPad Prism 8 was used for the multi-target single hit model fitting and cell survival curves were plotted.

Cell proliferation analysis. 3-(4,5-dimethylthiazolyl)-2,5-diphenyltetrazolium bromide (MTT; Solarbio Life Science, Beijing, China) was used to evaluate the impact of *FANCD2* silencing on the proliferation of CNE-2 cells after irradiation. Cells in the logarithmic growth phase were seeded into 96-well plates at 2000 cells per well. Radiation of 0 or 6 Gy was administered after cell adhesion. The optical density (OD) values at 450 nm of the cells in each group were measured 24, 48, 72, and 96 h after irradiation, and cell proliferation curves were plotted.

Cell apoptosis assay. Cells in the logarithmic growth phase in each group were inoculated into 6-well plates at a

concentration of 1×10^5 cells/ml. Radiation of 0 or 6 Gy was administered after cell adhesion. Apoptosis was evaluated at 72 h after irradiation using the Annexin-V-PE/7AAD apoptosis detection kit according to the manufacturer's instructions (BD Biosciences, USA). Annexin-V staining and 7AAD staining were evaluated as follows: annexin-V positive (+) and 7AAD negative (-) represented early apoptotic cells (right lower quadrant), while annexin-V (+) and 7AAD (+) represented late apoptotic and necrotic cells (upper right quadrant). The data were analyzed using flow cytometry data analysis.

Cell cycle assay. Cells in the logarithmic growth phase were diluted to a preset concentration as needed and inoculated into 6 cm dishes. Radiation of 0 or 6 Gy was administered after cell adhesion. The cells were analyzed by flow cytometry 48 h after irradiation. The detection methods and procedures were performed according to the manufacturer's instructions of the cell cycle reagent kit (BD Biosciences, USA). The data were statistically processed to obtain the cell cycle phase distribution ratio of the experimental cells.

Animal experiments. BALB/c-nu nude mice (female) aged 3–4 weeks and weighing 10–13 g were purchased from Chengdu DaShuo Biological Technology Co., Ltd., China. The mice were housed in a specific pathogen-free (SPF) experimental animal room at the Department of Oncology, Affiliated Hospital of Southwest Medical University. All animal studies followed the National Institutes of Health Guide for the Care and Use of Laboratory Animals. The nude mice were randomly divided into three groups with four mice per group. The animals were fed for 1 week, after which cells in the exponential growth phase were prepared in PBS to obtain a 1×10^7 /ml cell suspension and inoculated (using a 1 ml syringe) into the lateral skin on the left posterior thigh of the nude mice. Each nude mouse was subcutaneously injected with a 200 μ l cell suspension. The xenograft formation rate and tumor formation time per group of nude mice were observed. Once visible xenografts formed, the maximal diameter a) and perpendicular short axis diameter b) were measured every 3 days, and the tumor volume ($V = \pi/6 \times a \times b^2$) was calculated. On day 22 after the cell inoculation, xenograft irradiation was performed once per day (2 Gy each session). Irradiation continued for 5 days. On the 18th day after the completion of irradiation, all nude mice were sacrificed by cervical dislocation. The nude mice were imaged, the tumor was completely removed, and the xenograft tumor was weighed and imaged. Each xenograft tumor was aliquoted into two portions for subsequent experiments. The animal experiments were performed according to the methods described in previous experiments [24].

DNA microarray technology for the screening of differentially expressed genes. An Agilent SurePrint G3 Human GE 8x60K Microarray Kit was used to detect the gene expression differences between the CNE-2sh experimental group and the CNE-2 control group. This experiment was completed by Capital Bio Corporation, Beijing, China. The *in*

vitro amplification and fluorescence labeling were performed using total RNA from cells in each group. After the expression values of all samples were obtained, the data were pre-processed and clustered. A fold ratio difference ≥ 2 and a p-value ≤ 0.05 were used as the screening criteria to determine the number of differentially expressed genes. Then, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway, and disease enrichment analyses were performed to analyze the differentially expressed genes. Finally, the differentially expressed genes were introduced into the gene database of the National Center for Biotechnology Information (NCBI) and the PubMed database individually to explore their major functions. After excluding genes that were not related to tumors or had a low-fold differential expression, the candidate genes located downstream of *FANCD2* were selected for PCR and western blot validation.

Western blot analysis. A western blot analysis was performed to detect the effect of *FANCD2* gene silencing and the protein expression levels of NUPR1, FLI1, and FGF21 in cells and xenograft tumors. The total protein was extracted from the cells and xenograft tumors. The protein samples were adjusted to the same concentration, separated by 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and transferred to a nitrocellulose membrane. The following primary antibodies were used: mouse anti-human monoclonal *FANCD2* (sc-20022, 1:300); rabbit anti-human monoclonal FGF21 (sc-81946, 1:1000); rabbit anti-human monoclonal FLI1 (sc-365294, 1:1000); and rabbit anti-human polyclonal p8/NUPR1 (sc-23283, 1:1000) from Santa Cruz Biotechnology, CA, USA. The samples were incubated with the primary antibodies overnight at 4°C, and the membrane was washed with Tris-buffered saline with Tween-20 (TBST). Then, the following secondary antibodies were added: sheep anti-rabbit secondary antibody (sc-2773, 1:2000) and horseradish peroxidase (HRP)-labelled goat anti-mouse secondary antibody (sc-516102, 1:2000) (Santa Cruz Biotechnology). The samples were incubated at room temperature for 2 h. The membrane was washed with TBST, BeyoECL luminescence solution was added, and the reaction was stopped by adding double-distilled water once the bands appeared in the dark.

Immunohistochemistry. Immunohistochemistry was used to detect the protein expression of NUPR1, FLI1, and FGF21 in the nude mouse xenograft tissues after irradiation. Conventional paraffin-embedded tumor tissues were serially sliced to a thickness of 4 μ m. The sections were conventionally deparaffinized, hydrated, and placed in an ethylenediamine-tetraacetic acid (EDTA) solution (pH 9.0) and microwaved for antigen retrieval. The sections were immersed in 3% H_2O_2 for 10 min, rinsed three times with PBS, and incubated with primary antibodies at 37°C for 1 h. The primary antibodies included an anti-p8 antibody (sc-23283, 1:200), anti-human FGF21 antibody (sc-81946, 1:250), and anti-FLI1 antibody (sc-365294, 1:700) (Santa Cruz Biotechnology). Then, the sections were incubated with a secondary antibody at room

temperature for 30 min. Diaminobenzidine (DAB) solution was added for color development; the sections were counterstained with hematoxylin, dehydrated and cleared with xylene, and mounted. The expression and localization of each protein in the xenograft tissues were observed under a microscope.

Statistical analysis. The experimental data are presented as the mean \pm SD, and a one-way ANOVA was used for the data comparisons. SPSS 20.0 and GraphPad Prism 8 software were used to analyze the experimental results and plot the curves. A p-value <0.05 was considered significant.

Results

Lentiviral-mediated shRNA interference significantly silenced FANCD2 expression in CNE-2 cells. The gene silencing effect was verified by fluorescence quantitative PCR and western blot analyses. The images were observed under a fluorescence microscope and conventional microscope after transfection (Figure 1A), and the fluorescence quantitative PCR results showed that the expression level of FANCD2 mRNA in the CNE-2sh group was significantly lower than that in the CNE-2 and CNE-2NC groups ($p<0.01$; Figure 1B). The western blot analysis results showed that the expression level of FANCD2 protein in the CNE-2sh group was signifi-

cantly lower than that in the CNE-2 and CNE-2NC groups and that the silencing efficiency reached 92.20% ($p<0.01$; Figures 1C, 1D).

The silencing of FANCD2 expression significantly inhibited the colony formation of CNE-2 cells. The colony formation results showed that the survival fraction in the three groups of cells did not significantly differ before irradiation ($p>0.05$), but as the radiation dose increased, the survival fraction in the three groups decreased. The colony formation rate in the CNE-2sh group was significantly lower than that in the control group ($p<0.05$; Figure 2). The cell survival curves were obtained by multi-target single hit model fitting of the colony formation rate. The results showed that the silencing of FANCD2 expression reduced the survival fraction of the CNE-2sh cells after irradiation.

FANCD2 silencing significantly inhibited the proliferation of CNE-2 cells. The MTT results showed that the proliferation levels in the CNE-2sh group were lower than those in the CNE-2 and CNE-2NC groups at 72 and 96 h after culture ($p<0.05$; Figure 3A). Moreover, the proliferation inhibition effect was enhanced over time after irradiation; the proliferation rate in the CNE-2sh group was significantly lower than that in the control groups after irradiation at the two time-points of 72 and 96 h ($p<0.01$; Figure 3B). Therefore, FANCD2 silencing significantly inhibited the proliferation of




Figure 1. FANCD2 expression in three groups of CNE-2 cells. A) The images were observed under a fluorescence microscope and a conventional microscope after transfection. B) Histogram of FANCD2 mRNA fluorescence quantitative PCR detection results in three groups of cells. C) Western blot analysis showing the FANCD2 protein expression level in the three groups of CNE-2 cells. D) Histogram of FANCD2 relative expression in the three groups of cells. ** $p<0.01$

NPC CNE-2 cells, and the proliferation inhibition effect was time-dependent. In addition, cell proliferation inhibition was enhanced after irradiation.

FANCD2 silencing significantly increased apoptosis in CNE-2 cells and induced cell cycle arrest at the G2/M phase after irradiation. A dose of 6 Gy of radiation was administered to the three groups of cells, and flow cytometry was used to evaluate apoptosis 72 h after irradiation. The results showed that the CNE-2sh group had a higher apoptosis rate than the CNE-2NC group and CNE-2 group ($p < 0.05$; Figure 4A). Flow cytometry was used to evaluate the cell cycle distribution 48 h after irradiation. The results showed that the proportion of cells in the G0/G1 phase and S phase in the CNE-2sh group was significantly lower than that in the cells in the CNE-2 and CNE-2NC groups, while the proportion of cells in the G2/M phase was significantly higher than that in the cells in the CNE-2 group and CNE-2NC group ($p < 0.05$; Figure 4B). These results indicate that *FANCD2* silencing significantly increased CNE-2 cell apoptosis after irradiation and induced cell cycle arrest at the G2/M phase.

FANCD2 silencing significantly inhibited the growth of CNE-2 cells *in vivo*. In each group, xenograft tumors formed and were visible by the naked eye within 5–7 days, and the tumor formation rate was 100%. The average tumor formation time was 6 days, and the tumor formation time did not significantly differ among the three groups of cells (Figure 5A). Before irradiation, on day 22 after inoculation, the tumor volume in the CNE-2sh group was $453.29 \pm 27.31 \text{ mm}^3$, which was significantly lower than that in the CNE-2NC group ($710.35 \pm 33.23 \text{ mm}^3$) and the CNE-2 group ($737.78 \pm 23.12 \text{ mm}^3$) ($p < 0.01$; Figure 5B). After irradiation, the volume of the xenograft tumors in the mice in the CNE-2sh experimental group no longer increased, and the final volume was $216.35 \pm 27.75 \text{ mm}^3$, which was significantly lower than that of the tumors in the mice in the CNE-2 group ($619.68 \pm 37.89 \text{ mm}^3$) and CNE-2NC group




Figure 2. FANCD2 silencing significantly reduced the survival fraction of CNE-2 cells after irradiation. The cell survival fraction in the three groups of cells after 14 days of radiation with 0, 2, 4, 6, and 8 Gy. * $p < 0.05$

($577.56 \pm 27.48 \text{ mm}^3$; $p < 0.01$; Figures 5B, 5C). In addition, the final weight of the xenograft tumors in the nude mice in the CNE-2sh experimental group after irradiation ($0.33 \pm 0.07 \text{ g}$) was significantly lower than that in the mice in the CNE-2 group ($1.20 \pm 0.28 \text{ g}$) and the CNE-2NC group ($1.10 \pm 0.19 \text{ g}$; $p < 0.01$; Figure 5D). These results suggest that *FANCD2* silencing inhibits CNE-2 cell growth *in vivo* and enhances their sensitivity to radiation therapy.

Screening for differentially expressed genes. An Agilent whole human genome microarray was used to detect different gene mRNA expression levels between the CNE-2sh group and CNE-2 group. The results showed that 313 genes were differentially expressed between the two groups of cells, including 193 genes that were upregulated and 120 genes that were downregulated in the CNE-2sh cells (Figure 6, Supplementary Table S1). GO and KEGG (Tables 1, 2) pathway analyses of the differentially expressed mRNAs were




Figure 3. Cell proliferation analysis using an MTT assay. A) At a radiation dose of 0 Gy, the OD values in the experimental group at 72 h and 96 h after conventional culture were significantly lower than those in the control group. B) The inhibition effect was more significant in the cells after receiving 6 Gy radiation therapy. FANCD2 silencing significantly inhibited the proliferation of CNE-2 cells, and the proliferation inhibition effect was time and dose-dependent. * $p < 0.05$, ** $p < 0.01$




Figure 4. Apoptosis and cell cycle distribution of cells in the three groups after 6 Gy of radiation. A) Apoptosis plot in which the right upper quadrant represents early apoptotic cells and the right lower quadrant represents late apoptotic and necrotic cells. B) Cell cycle distribution and proportion of cells in different phases. *p<0.05




Figure 5. FANCD2 silencing inhibits the growth of xenograft tumors of CNE-2 cells. A) Images of nude mice 40 days after CNE-2 cells were transplanted into the three groups of mice. B) Changes in the tumor volume from 7 days after inoculation to the end of the experiment; irradiation was performed 22 days after inoculation. C) An intact xenograft tumor in a nude mouse. D) Histogram of xenograft tumor weight in nude mice. The xenograft tumor volume and weight in the CNE-2sh group were significantly lower than those in the control group. *p<0.05, **p<0.01

performed. The differentially expressed genes involved in molecular functions were sorted according to the fold differences, and *FGF21*, *FLI1*, and *NUPR1* were selected as the top three differentially expressed genes for the subsequent experiments. DNA microarray showed the original signal value of *NUPR1*, *FLI1*, and *FGF21* in the cells of the experimental group was significantly lower than that in the control groups ($p < 0.05$; Table 3). PCR validation showed that the relative mRNA expression of *NUPR1*, *FLI1*, and *FGF21* in the cells in the experimental group was significantly lower than that in the control groups ($p < 0.05$; Table 4).

FANCD2 silencing downregulated the FGF21, FLI1, and NUPR1 protein expression levels in CNE-2 cells. The western blot analysis showed that the FGF21, FLI1, and NUPR1 protein expression levels in the CNE-2sh group were downregulated compared to those in the control CNE-2




Figure 6. Volcano plot of the differences in gene expression between CNE-2 and CNE-2sh cells. Each rectangle in the figure represents the relative expression level of each gene in different samples. The high-expression genes are marked in red, and the low-expression genes are marked in blue.

Table 1. GO enrichment analysis of the differentially expressed genes based on DAVID 6.8 ($p < 0.05$).

GO Analysis	Enrichment Terms	p-value	Benjamini	
BP Analysis	GO:0007165~signal transduction	0.001	0.699	
	GO:0010951~negative regulation of endopeptidase activity	0.002	0.619	
	GO:0007267~cell-cell signalling	0.005	0.865	
	GO:0048546~digestive tract morphogenesis	0.008	0.890	
	GO:0032956~regulation of actin cytoskeleton organization	0.013	0.947	
	GO:0009615~response to virus	0.029	0.995	
	GO:0030574~collagen catabolic process	0.030	0.992	
	GO:0070328~triglyceride homeostasis	0.030	0.986	
	GO:0060326~cell chemotaxis	0.031	0.979	
	GO:0015721~bile acid and bile salt transport	0.032	0.974	
	GO:0016477~cell migration	0.035	0.973	
	GO:0070374~positive regulation of ERK1 and ERK2 cascade	0.037	0.971	
	GO:0070098~chemokine-mediated signalling pathway	0.039	0.965	
	GO:2000660~negative regulation of interleukin-1-mediated signalling pathway	0.041	0.965	
GO:0022617~extracellular matrix disassembly	0.046	0.969		
CC Analysis	GO:0005615~extracellular space	0.000	0.009	
	GO:0005576~extracellular region	0.002	0.189	
	GO:0005578~proteinaceous extracellular matrix	0.002	0.160	
	GO:0030175~filopodium	0.007	0.317	
	GO:0031410~cytoplasmic vesicle	0.014	0.445	
	GO:0005737~cytoplasm	0.016	0.448	
	GO:0016328~lateral plasma membrane	0.019	0.447	
	GO:0090498~extrinsic component of Golgi membrane	0.032	0.580	
	GO:0070062~extracellular exosome	0.034	0.559	
	GO:0009925~basal plasma membrane	0.041	0.591	
	MF Analysis	GO:0004867~serine-type endopeptidase inhibitor activity	0.004	0.703
		GO:0004896~cytokine receptor activity	0.006	0.655
		GO:0008009~chemokine activity	0.015	0.811
		GO:0005201~extracellular matrix structural constituent	0.034	0.943
GO:0042169~SH2 domain binding		0.037	0.920	

Abbreviations: BP-biological process; CC-cellular component; MF-molecular function

group ($p < 0.05$). After irradiation, FGF21, FLI1, and NUPR1 protein expressions were examined again in the cells in the experimental and control groups, and the results showed the same trend; the difference was significant ($p < 0.05$; Figures 7A, 7B). In addition, the western blot and immunohistochemistry analyses of the CNE-2 xenograft tumors after irradiation in the nude mice showed that FGF21, FLI1, and NUPR1 protein expression in the CNE-2sh xenografts after irradiation was significantly downregulated compared to that in the CNE-2 control group ($p < 0.05$; Figures 7C, 7D, 8, and 9). These results are consistent with those of the *in vitro* cell experiments.

Discussion

Studies have shown that a functional dysfunction of *FANCD2*, which is a key protein in the FA pathway, can lead to the inactivation of the FA pathway, which, in turn, increases the sensitivity of cells to DNA cross-linking damage. Li et al. showed that *FANCF* silencing increased the sensitivity of the anticancer drug mitoxantrone by inhibiting the monoubiquitination of *FANCD2* and that the mechanism of its enhanced sensitivity is related to the inhibition of the *in vitro* proliferation of the breast cancer cell lines MCF-7 and T-47D [25]. The silencing of *FANCD2*, *FANCF*, and *FANCL* by siRNA technology significantly reversed the cisplatin resistance of A549/DDP lung cancer cells and increased their sensitivity to cisplatin treatment by directly inhibiting the FA/BRCA DNA repair pathway, increasing cisplatin-induced DNA

damage in lung cancer cells, inhibiting tumor cell proliferation, and promoting apoptosis [26]. Our study results showed that after *FANCD2* silencing by shRNA interference, the proliferation activity of CNE-2sh cells in the experimental group was significantly inhibited *in vivo* and *in vitro*, and the apoptosis rate increased. These findings indicate that *FANCD2* silencing by lentiviral-mediated shRNA interference inhibited the proliferation of NPC CNE-2 cells and that the radiosensitivity effect of silencing *FANCD2* is related to cell proliferation.

Cell cycle regulation plays an important role in tumor cell proliferation, apoptosis, and ionizing radiation sensitization. Pawlik et al. demonstrated that in the DNA damage repair process, cells are arrested in the G2/M phase, and cells in the G2/M phase are more susceptible to the cytotoxic effects of ionizing radiation [27]. The induction of cell cycle arrest at the G2/M phase in tumor cells may be an effective strategy for enhancing the ionizing radiation effect against tumors [28]. Numerous recent studies have shown that increasing radiation-induced G2/M phase arrest in tumor cells can significantly increase the sensitivity of HNSCC, cervical cancer, and prostate cancer cells to ionizing radiation [29–32]. In the present study, the cell cycle detection results after irradiation showed that the proportion of cells in the G2/M phase in the CNE-2sh group was significantly higher than that in the control group cells, indicating that *FANCD2* silencing significantly increased radiation-induced G2/M phase cell cycle arrest in the CNE-2 cells and enhanced their ionizing radiation sensitivity. Interestingly, in ionizing radiation sensitivity experiments involving bone marrow stromal cells and IL-3-dependent hematopoietic stem cells of *FANCD2*-deficient mice, Berhane et al. found that the growth life of bone marrow stromal cells was shortened and showed strong radiation sensitivity and DNA damage involvement. However, there was no obvious radiation-induced G2/M arrest [33]. These results indicate that many factors affect the radiation sensitivity of tumor cells and that different tumor cells may exhibit different responses after irradiation; however, the specific mechanism still requires

Table 2. KEGG pathway enrichment analysis of the differentially expressed genes based on DAVID 6.8 ($p < 0.05$).

Enrichment Analysis of KEGG Pathways	p value	Benjamini
hsa05146: Amoebiasis	<0.001	0.017
hsa04060: Cytokine-cytokine receptor interaction	0.004	0.253
hsa04620: Toll-like receptor signaling pathway	0.005	0.228
hsa05202: Transcriptional misregulation in cancer	0.030	0.703
hsa04062: Chemokine signaling pathway	0.045	0.766

Table 3. The relative expression (original signal value) of three differential tumor-associated genes in CNE-2 and CNE-2sh cells detected by a DNA microarray (mean \pm SD).

Gene symbol	CNE-2 (wide type)	CNE-2sh (<i>FANCD2</i> ^{-/-})	T-value	p-value
NUPR1	13,907.89 \pm 3520.28	3933.00 \pm 509.67	4.857	0.037*
FLI1	278.60 \pm 35.72	117.751 \pm 9.07	7.558	0.002*
FGF21	663.73 \pm 78.37	143.32 \pm 18.53	11.193	0.005*

*Statistically significant ($p < 0.05$)

Table 4. The relative mRNA expression ($2^{-\Delta\Delta C_t}$ value) of NUPR1, FLI1 and FGF21 mRNA in each group of cells detected by RT-qPCR (mean \pm SD).

Gene symbol	CNE-2 (wide type)	CNE-2sh (<i>FANCD2</i> ^{-/-})	T-value	p value
NUPR1	1.000 \pm 0.000	0.148 \pm 0.005	322.026	<0.001*
FLI1	1.000 \pm 0.000	0.434 \pm 0.017	57.568	<0.001*
FGF21	1.000 \pm 0.000	0.236 \pm 0.016	84.715	<0.001*

*Statistically significant ($p < 0.05$)




Figure 7. FANCD2 silencing decreases NUPR1, FLI1, and FGF21 protein expression in CNE-2 cells after irradiation *in vitro* and *in vivo*. A, B) Detection of FGF21, FLI1, and NUPR1 protein expression in CNE-2sh cells and CNE-2 cells using western blotting before and after irradiation; C, D) Detection of FGF21, FLI1, and NUPR1 protein expression in CNE-2sh xenografts and CNE-2NC xenografts using western blotting. CNE-2+R and CNE-2sh+R represent the radiation exposure group. * $p < 0.05$, ** $p < 0.01$




Figure 8. Immunohistochemistry analysis of FGF21, FLI1, and NUPR1 protein expression in nude mouse xenografts after irradiation. NUPR1 and FLI1 expression were mainly evident in the nucleus and in the cytoplasm. FGF21 expression was mainly located in the cytoplasm (magnification, 400 \times).




Figure 9. Image-Pro Plus 6 software was used to analyze the relative absorbance values of FGF21, FLI1, and NUPR1 protein in tumors after irradiation. The average absorbance values of FGF21, FLI1, and NUPR1 in the CNE-2sh group were significantly lower than those in the control group CNE-2. * $p < 0.05$, ** $p < 0.01$

further study. Apoptosis refers to the programmed death of living cells, is regulated by gene expression, and is morphologically different from necrosis. Apoptosis is also an important indicator used to measure the radiation sensitivity of tumor cells. Levine et al. reported that the number of spontaneously apoptotic cells in tumor tissue before irradiation is a powerful predictor of the radiation response [34]. Numerous recent studies have shown that apoptosis is an important factor affecting the ionizing radiation sensitivity of NPC cells [35, 36]. The flow cytometry analysis in our research demonstrated that *FANCD2* silencing increased CNE-2 cell apoptosis after irradiation. These results indicate that silencing *FANCD2* gene expression significantly increased radiation-induced apoptosis in CNE-2 cells and enhanced the ionizing radiation sensitivity.

NUPR1 was originally identified as p8, which is a gene that is preferentially upregulated during the acute inflammatory phase of the cellular stress response in a rat pancreatitis model [37]. Previous studies have confirmed that *NUPR1* can significantly promote tumor cell growth. Ree et al. demonstrated that *NUPR1* is involved in early breast cancer growth and mediates distant breast cancer metastasis [38]. Recent studies have reported that mitochondrial dysfunction in *NUPR1*-deficient pancreatic cancer cells leads to increased glycolysis, reduced ATP production, and impaired cellular stress response, thereby promoting programmed cell death [39]. Zeng et al. [40] found that knocking out *NUPR1* inhibits the growth of U266 and RPMI8226 multiple myeloma cell lines via the activation of PTEN and caspase-dependent apoptosis. This study found that *FANCD2* silencing downregulated *NUPR1* expression, inhibited cell proliferation, and promoted apoptosis, however, its specific mechanism needs to be further studied. *FLI1* is a member of the ETS transcription factor family and is usually expressed in hematopoietic cells, including most immune-active cells [41], heart cells, lung

cells, and ovarian cells [42, 43]. However, limited attention has been paid to the role of *FLI1* in epithelial tumors [44]. The *FLI1* gene encodes a transcription factor containing a DNA binding domain, and this gene can be translocated with the Ewing sarcoma (*EWS*) gene located on chromosome 22 by T(11; 22)(q24; q12) to form a fusion gene *EWS-FLI1*. Franzetti et al. showed that *EWS-FLI1* regulates cell proliferation and migration through a MAPK-independent pathway. High levels of *EWS-FLI1* promote ES proliferation, while low levels of *EWS-FLI1* drive tumor cell migration [45]. Similarly, in a study investigating the relationship among the glucocorticoid receptor (GR), Ewing's sarcoma and juvenile bone malignant tumors, Srivastava et al. found that GR combined with specific regions of *FLI1* can enhance GR transcription activity, thereby promoting tumor proliferation and migration [46]. In addition, studies have shown that the FGF family plays an important role in tumorigenesis and progression. The upregulated expression of various typical *FGFs* (including *FGF1*, *FGF2*, and *FGF 6-9*) derived from tumor cells or stromal cells can induce the occurrence and progression of various tumors and cancers [47, 48]. Kang et al. showed that *FGF21* was highly expressed in papillary thyroid carcinoma patients' serum and that its expression level was positively correlated with the tumor stage, vascular lymphatic invasion, and recurrence. The underlying mechanism proposed was that *FGF21* promotes tumor growth and invasion through the regulation of the signal axis of the *FGFR* pathway [49]. Studies in China reported that the transient silencing of *FGF21* increased the sorafenib-induced inhibition of hepatocellular carcinoma cell proliferation [50]. However, animal experiments have shown that *FGF21* is highly expressed in mouse pancreatic acinar cells and that the activation of the proto-oncogene *KRAS* can significantly reduce *FGF21* expression. The injection of recombinant *FGF21* can significantly reduce pancreatic inflammation and tumorigenesis, and its specific mechanism is that *FGF21* can decrease the ability of RAS to bind guanosine triphosphate. Therefore, it is speculated that *FGF21* can be used for the prevention and treatment of pancreatic cancer [51]. The above results indicate that *NUPR1*, *FGF21*, and *FLI1* promote tumor growth in certain tumors. Interestingly, in this study, the expression levels of *NUPR1*, *FGF21*, and *FLI1* were all downregulated after *FANCD2* silencing. Cell proliferation was inhibited both *in vitro* and *in vivo*, apoptosis was increased, and the cell cycle was arrested at the G2/M phase after irradiation, which is consistent with the findings in most studies showing that *NUPR1*, *FGF21*, and *FLI1* play roles in promoting tumor growth.

In conclusion, the results of this study indicate that *FANCD2* silencing can significantly enhance the ionizing radiation sensitivity of NPC CNE-2 cells. We demonstrate that the mechanism underlying the increased radiosensitivity may be related to the regulation of the expression of the proteins *NUPR1*, *FGF21*, and *FLI1*. Our investigation suggests that *FANCD2* is a promising target for NPC radiation therapy.

Supplementary information is available in the online version of the paper.

Acknowledgments: The present study was supported by the Joint Research Project of Science Technology Department of Sichuan Province, Office of Science Technology of Luzhou and Luzhou Medical College (Grant No. 14JC0182), the General Program of National Natural Science Foundation of China (Grant No. 81773529), and the Applied Basic Research Programs Foundation of Sichuan Province (Grant No. 2017JY0109), China.

References

- [1] WEI KR, ZHENG RS, ZHANG SW, LIANG ZH, LI ZM et al. Nasopharyngeal carcinoma incidence and mortality in china, 2013. *Chin J Cancer* 2017; 36: 90. <https://doi.org/10.1186/s40880-017-0257-9>
- [2] HALESHAPPA RA, THANKY AH, KUNTEGOWDANAHALI L, KANAKASETTY GB, DASAPPA L et al. Epidemiology and outcomes of nasopharyngeal carcinoma: Experience from a regional cancer center in southern india. *South Asian J Cancer* 2017; 6: 122–124. <https://doi.org/10.4103/2278-330X.214578>
- [3] TORRE LA, BRAY F, SIEGEL RL, FERLAY J, LORTET-TIEULENT J et al. Global cancer statistics, 2012. *CA Cancer J Clin* 2015; 65: 87–108. <https://doi.org/10.3322/caac.21262>
- [4] CHEN W, ZHENG R, BAADE PD, ZHANG S, ZENG H et al. Cancer statistics in china, 2015. *CA Cancer J Clin* 2016; 66: 115–132. <https://doi.org/10.3322/caac.21338>
- [5] JI X, ZHANG W, XIE C, WANG B, ZHANG G et al. Nasopharyngeal carcinoma risk by histologic type in central china: Impact of smoking, alcohol and family history. *Int J Cancer* 2011; 129: 724–732. <https://doi.org/10.1002/ijc.25696>
- [6] BROSH RM, JR., BELLANI M, LIU YSEIDMAN MM. Fanconi anemia: A DNA repair disorder characterized by accelerated decline of the hematopoietic stem cell compartment and other features of aging. *Ageing Res Rev* 2017; 33: 67–75. <https://doi.org/10.1016/j.arr.2016.05.005>
- [7] TANIGUCHI TD'ANDREA AD. Molecular pathogenesis of fanconi anemia: Recent progress. *Blood* 2006; 107: 4223–4233. <https://doi.org/10.1182/blood-2005-10-4240>
- [8] VUNDINTI BR, KORGAONKAR SGHOSH K. Incidence of malignancy and clonal chromosomal abnormalities in fanconi anemia. *Indian J Cancer* 2010; 47: 397–399. <https://doi.org/10.4103/0019-509X.73575>
- [9] MAMRAK NE, SHIMAMURA AHOWLETT NG. Recent discoveries in the molecular pathogenesis of the inherited bone marrow failure syndrome fanconi anemia. *Blood Rev* 2017; 31: 93–99. <https://doi.org/10.1016/j.blre.2016.10.002>
- [10] KNIES K, INANO S, RAMIREZ MJ, ISHIAI M, SURRELLES J et al. Biallelic mutations in the ubiquitin ligase rfd3 cause fanconi anemia. *J Clin Invest* 2017; 127: 3013–3027. <https://doi.org/10.1172/JCI92069>
- [11] INANO S, SATO K, KATSUKI Y, KOBAYASHI W, TANAKA H et al. Rfd3-mediated ubiquitination promotes timely removal of both rpa and rad51 from DNA damage sites to facilitate homologous recombination. *Mol Cell* 2017; 66: 622–634 e628. <https://doi.org/10.1016/j.molcel.2017.04.022>
- [12] NALEPA GCLAPP DW. Fanconi anaemia and cancer: An intricate relationship. *Nat Rev Cancer* 2018; 18: 168–185. <https://doi.org/10.1038/nrc.2017.116>
- [13] KUTLER DI, AUERBACH AD, SATAGOPAN J, GIAMPIETRO PF, BATISH SD et al. High incidence of head and neck squamous cell carcinoma in patients with fanconi anemia. *Arch Otolaryngol Head Neck Surg* 2003; 129: 106–112. <https://doi.org/10.1001/archotol.129.1.106>
- [14] HAN B, SHEN Y, ZHANG P, JAYABAL P, CHE R et al. Overlooked fancd2 variant encodes a promising, portent tumor suppressor, and alternative polyadenylation contributes to its expression. *Oncotarget* 2017; 8: 22490–22500. <https://doi.org/10.18632/oncotarget.14989>
- [15] SHEN Y, ZHANG J, YU HFEI P. Advances in the understanding of fanconi anemia complementation group d2 protein (fancd2) in human cancer. *Cancer Cell Microenviron* 2015; 2: e986. <https://doi.org/10.14800/ccm.986>
- [16] CHE R, ZHANG J, NEPAL M, HAN BFEI P. Multifaceted fanconi anemia signaling. *Trends Genet* 2018; 34: 171–183. <https://doi.org/10.1016/j.tig.2017.11.006>
- [17] PARK E, KIM H, KIM JM, PRIMACK B, VIDAL-CARDENAS S et al. Fancd2 activates transcription of tap63 and suppresses tumorigenesis. *Mol Cell* 2013; 50: 908–918. <https://doi.org/10.1016/j.molcel.2013.05.017>
- [18] ATALA A. Re: Endogenous formaldehyde is a hematopoietic stem cell genotoxin and metabolic carcinogen. *J Urol* 2016; 196: 279–280. <https://doi.org/10.1016/j.juro.2016.03.155>
- [19] KAIS Z, RONDINELLI B, HOLMES A, O'LEARY C, KOZONO D et al. Fancd2 maintains fork stability in brca1/2-deficient tumors and promotes alternative end-joining DNA repair. *Cell Rep* 2016; 15: 2488–2499. <https://doi.org/10.1016/j.celrep.2016.05.031>
- [20] MICHL J, ZIMMER J, BUFFA FM, MCDERMOTT UTAR-SOUNAS M. Fancd2 limits replication stress and genome instability in cells lacking brca2. *Nat Struct Mol Biol* 2016; 23: 755–757. <https://doi.org/10.1038/nsmb.3252>
- [21] KAUFFMANN A, ROSSELLI F, LAZAR V, WINNEPENINCKX V, MANSUET-LUPO A et al. High expression of DNA repair pathways is associated with metastasis in melanoma patients. *Oncogene* 2008; 27: 565–573. <https://doi.org/10.1038/sj.onc.1210700>
- [22] OZAWA H, IWATSUKI M, MIMORI K, SATO T, JOHANSSON F et al. Fancd2 mrna overexpression is a bona fide indicator of lymph node metastasis in human colorectal cancer. *Ann Surg Oncol* 2010; 17: 2341–2348. <https://doi.org/10.1245/s10434-010-1002-7>
- [23] PATIL AA, SAYAL P, DEPOND ML, BEVERIDGE RD, ROYLANCE A et al. Fancd2 re-expression is associated with glioma grade and chemical inhibition of the fanconi anaemia pathway sensitises gliomas to chemotherapeutic agents. *Oncotarget* 2014; 5: 6414–6424. <https://doi.org/10.18632/oncotarget.2225>
- [24] FENG HJ, BAO YL, LIANG ZP, ZHAO FP, XU SE et al. Silencing of fancd2 enhances the radiosensitivity of metastatic cervical lymph node-derived head and neck squamous cell carcinoma hsc-4 cells. *Int J Oncol* 2017. <https://doi.org/10.3892/ijo.2017.3902>

- [25] LI Y, ZHAO L, SUN H, YU J, LI N et al. Gene silencing of *fancl* potentiates the sensitivity to mitoxantrone through activation of *jnk* and *p38* signal pathways in breast cancer cells. *PLoS One* 2012; 7: e44254. <https://doi.org/10.1371/journal.pone.0044254>
- [26] DAI CH, LI J, CHEN P, JIANG HG, WU M et al. Rna interferences targeting the *fanconi anemia/brca* pathway upstream genes reverse cisplatin resistance in drug-resistant lung cancer cells. *J Biomed Sci* 2015; 22: 77. <https://doi.org/10.1186/s12929-015-0185-4>
- [27] PAWLIK TMKEYOMARSI K. Role of cell cycle in mediating sensitivity to radiotherapy. *Int J Radiat Oncol Biol Phys* 2004; 59: 928–942. <https://doi.org/10.1016/j.ijrobp.2004.03.005>
- [28] HEMATULIN A, MEETHANG S, INGKANINAN KSA-GAN D. *Derris scandens* benth extract potentiates radioresistance of hep-2 laryngeal cancer cells. *Asian Pac J Cancer Prev* 2012; 13: 1289–1295. <https://doi.org/10.7314/apjcp.2012.13.4.1289>
- [29] LIU J, GE YY, ZHU HC, YANG X, CAI J et al. Fenofibrate increases radiosensitivity in head and neck squamous cell carcinoma via inducing *g2/m* arrest and apoptosis. *Asian Pac J Cancer Prev* 2014; 15: 6649–6655. <https://doi.org/10.7314/apjcp.2014.15.16.6649>
- [30] DENG YR, CHEN XJ, CHEN W, WU LF, JIANG HP et al. *Sp1* contributes to radioresistance of cervical cancer through targeting *g2/m* cell cycle checkpoint *cdk1*. *Cancer Manag Res* 2019; 11: 5835–5844. <https://doi.org/10.2147/CMAR.S200907>
- [31] CHEN YA, TZENG DTW, HUANG YP, LIN CJ, LO UG et al. Antrocin sensitizes prostate cancer cells to radiotherapy through inhibiting *pi3k/akt* and *mapk* signaling pathways. *Cancers (Basel)* 2018; 11: 34. <https://doi.org/10.3390/cancers11010034>
- [32] PAN W, GONG S, WANG J, YU L, CHEN Y et al. A nuclear-targeted titanium dioxide radiosensitizer for cell cycle regulation and enhanced radiotherapy. *Chem Commun (Camb)* 2019; 55: 8182–8185. <https://doi.org/10.1039/c9cc01651a>
- [33] BERHANE H, EPPERLY MW, GOFF J, KALASH R, CAO S et al. Radiologic differences between bone marrow stromal and hematopoietic progenitor cell lines from *fanconi anemia (fancl2(-/-))* mice. *Radiat Res* 2014; 181: 76–89. <https://doi.org/10.1667/RR13405.1>
- [34] LEVINE EL, DAVIDSON SE, ROBERTS SA, CHADWICK CA, POTTEN CS et al. Apoptosis as predictor of response to radiotherapy in cervical carcinoma. *Lancet* 1994; 344: 472. [https://doi.org/10.1016/s0140-6736\(94\)91802-3](https://doi.org/10.1016/s0140-6736(94)91802-3)
- [35] HE Y, JING Y, WEI F, TANG Y, YANG L et al. Long non-coding rna *pvt1* predicts poor prognosis and induces radioresistance by regulating DNA repair and cell apoptosis in nasopharyngeal carcinoma. *Cell Death Dis* 2018; 9: 235. <https://doi.org/10.1038/s41419-018-0265-y>
- [36] WANG W, LI J, WEN Q, LUO J, CHU S et al. *4egi-1* induces apoptosis and enhances radiotherapy sensitivity in nasopharyngeal carcinoma cells via *dr5* induction on *4e-bp1* dephosphorylation. *Oncotarget* 2016; 7: 21728–21741. <https://doi.org/10.18632/oncotarget.7824>
- [37] MALLO GV, FIEDLER F, CALVO EL, ORTIZ EM, VASSEUR S et al. Cloning and expression of the rat *p8* cDNA, a new gene activated in pancreas during the acute phase of pancreatitis, pancreatic development, and regeneration, and which promotes cellular growth. *J Biol Chem* 1997; 272: 32360–32369. <https://doi.org/10.1074/jbc.272.51.32360>
- [38] REE AH, PACHECO MM, TVERMYR M, FODSTAD OBRENTANI MM. Expression of a novel factor, *com1*, in early tumor progression of breast cancer. *Clin Cancer Res* 2000; 6: 1778–1783.
- [39] SANTOFIMIA-CASTANO P, LAN W, BINTZ J, GAYET O, CARRIER A et al. Inactivation of *nupr1* promotes cell death by coupling er-stress responses with necrosis. *Sci Rep* 2018; 8: 16999. <https://doi.org/10.1038/s41598-018-35020-3>
- [40] ZENG C, LI X, LI A, YI B, PENG X et al. Knockdown of *nupr1* inhibits the growth of *u266* and *rpmi8226* multiple myeloma cell lines via activating *pten* and caspase activation dependent apoptosis. *Oncol Rep* 2018; 40: 1487–1494. <https://doi.org/10.3892/or.2018.6544>
- [41] SUZUKI E, WILLIAMS S, SATO S, GILKESON G, WATSON DK et al. The transcription factor *fli-1* regulates monocyte, macrophage and dendritic cell development in mice. *Immunology* 2013; 139: 318–327. <https://doi.org/10.1111/imm.12070>
- [42] BEN-DAVID Y, GIDDENS EBBERNSTEIN A. Identification and mapping of a common proviral integration site *fli-1* in erythroleukemia cells induced by friend murine leukemia virus. *Proc Natl Acad Sci U S A* 1990; 87: 1332–1336. <https://doi.org/10.1073/pnas.87.4.1332>
- [43] BEN-DAVID Y, GIDDENS EB, LETWIN KBERNSTEIN A. Erythroleukemia induction by friend murine leukemia virus: Insertional activation of a new member of the *ets* gene family, *fli-1*, closely linked to *c-ets-1*. *Genes Dev* 1991; 5: 908–918. <https://doi.org/10.1101/gad.5.6.908>
- [44] SCHEIBER MN, WATSON PM, RUMBOLDT T, STANLEY C, WILSON RC et al. *Fli1* expression is correlated with breast cancer cellular growth, migration, and invasion and altered gene expression. *Neoplasia* 2014; 16: 801–813. <https://doi.org/10.1016/j.neo.2014.08.007>
- [45] FRANZETTI GA, LAUD-DUVAL K, VAN DER ENT W, BRISAC A, IRONDELLE M et al. Cell-to-cell heterogeneity of *ewsr1-fli1* activity determines proliferation/migration choices in ewing sarcoma cells. *Oncogene* 2017; 36: 3505–3514. <https://doi.org/10.1038/onc.2016.498>
- [46] SRIVASTAVA S, NATARAJ NB, SEKAR A, GHOSH S, BORNSTEIN C et al. *Ets* proteins bind with glucocorticoid receptors: Relevance for treatment of ewing sarcoma. *Cell Rep* 2019; 29: 104–117 e104. <https://doi.org/10.1016/j.celrep.2019.08.088>
- [47] TURNER NGROSE R. Fibroblast growth factor signalling: From development to cancer. *Nat Rev Cancer* 2010; 10: 116–129. <https://doi.org/10.1038/nrc2780>
- [48] ACEVEDO VD, GANGULA RD, FREEMAN KW, LI R, ZHANG Y et al. Inducible *fgfr-1* activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. *Cancer Cell* 2007; 12: 559–571. <https://doi.org/10.1016/j.ccr.2007.11.004>

-
- [49] KANG YE, KIM JT, LIM MA, OH C, LIU L et al. Association between circulating fibroblast growth factor 21 and aggressiveness in thyroid cancer. *Cancers (Basel)* 2019; 11: 1154. <https://doi.org/10.3390/cancers11081154>
- [50] LIU M, ZHOU R, WU X, XU X, SU M et al. Clinicopathologic characterization of sorafenib-induced endoplasmic reticulum stress in human liver cancer cells. *J Physiol Pharmacol* 2018; 69: 4. <https://doi.org/10.26402/jpp.2018.4.08>
- [51] LUO Y, YANG Y, LIU M, WANG D, WANG F et al. Oncogenic kras reduces expression of fgf21 in acinar cells to promote pancreatic tumorigenesis in mice on a high-fat diet. *Gastroenterology* 2019; 157: 1413–1428 e1411. <https://doi.org/10.1053/j.gastro.2019.07.030>